TABLE 2.

Univariate Binary Logistic Regression for Achieving SVR for Interferon-naïve Patients With HCV-associated HCC Within Milan Criteria Who Underwent Liver Transplantation

	Logistic Regression
	OR (95% CI)	P value
Age at diagnosis (median, IQR)	1.03 (0.98–1.07)	0.31
Sex
Female	Reference
Male	0.46 (0.19–1.11)	0.08
Race/Ethnicity
White	Reference
Black	0.55 (0.27–2.09)	0.55
Asian	1.74 (0.22–13.75)	1.74
Latino	1.05 (0.44–2.51)	1.05
ASA
I	Reference
II	–	–
III	–	–
IV	–	–
Functional status
Independent	Reference
Partially dependent	1.18 (0.58–2.40)	0.65
Totally dependent	1.14 (0.14–9.46)	0.91
DAA regimen
Sofosbuvir/velpatasvir	Reference
Ledipasvir/sofosbuvir	0.48 (0.11–2.11)	0.33
Glecaprevir/pibrentasvir	0.24 (0.05–1.18)	0.08
Other	0.38 (0.08–1.77)	0.22
Timing of DAA therapy
Pre-LT	Reference
0–3 mo post LT	1.42 (0.41–4.93)	0.58
≥3 mo post LT	0.36 (0.20–0.65)	<0.01
Received liver-directed therapy
No	Reference
Yes	1.33 (0.56–3.16)	0.52
Deceased donor
Deceased donor	Reference
Living donor	–	–
HCV+ donor liver
No	Reference
Yes	0.65. (0.31–1.34)	0.24
Any postoperative complication
No	Reference
Yes	0.60 (0.34–1.07)	0.08
Acute rejection
No	Reference
Yes	1.47 (0.56–3.87)	0.44
Retransplant
No	Reference
Yes	–
Months on waitlist	1.01 (0.99–1.03)	0.38